Literature DB >> 6754513

Inhibition of disaccharide digestion in rat intestine by the alpha-glucosidase inhibitor acarbose (BAY g 5421).

H P Krause, U Keup, W Puls.   

Abstract

Administration of the alpha-glucosidase inhibitor, acarbose (BAY g 5421), to rats together with a sucrose load results in a marked retardation of sucrose digestion. The carbohydrate content of the small intestine is dose dependently increased; the time needed for the absorption is doubled. In the large intestine significant amounts of carbohydrate can be found only after administration of high doses of acarbose (2-4 mg/kg p.o.). In oral sucrose and maltose loading tests the blood glucose increase is dose dependently reduced by acarbose (ED50, 1 or 12 mg/kg, respectively). In perfused jejunal loops of rats, acarbose inhibits the absorption of sucrose (4 g/l) and maltose (1 and 2 g/l), the IC50 values being 3.2, 36, and 57 micrograms/ml, respectively. The data indicate that acarbose effectively inhibits sucrose digestion. It is 10-20 times less effective with maltose as a substrate. Slight malabsorption is induced by acarbose only in doses higher than the ED50.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6754513     DOI: 10.1159/000198755

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

Review 1.  Endothelial dysfunction, inflammation and diabetes.

Authors:  Paresh Dandona; Ahmad Aljada; Ajay Chaudhuri; Priya Mohanty
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Inhibitory effect and mechanism of acarbose combined with gymnemic acid on maltose absorption in rat intestine.

Authors:  H Luo; L F Wang; T Imoto; Y Hiji
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 3.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 4.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

5.  Modulation of starch digestion for slow glucose release through "toggling" of activities of mucosal α-glucosidases.

Authors:  Byung-Hoo Lee; Razieh Eskandari; Kyra Jones; Kongara Ravinder Reddy; Roberto Quezada-Calvillo; Buford L Nichols; David R Rose; Bruce R Hamaker; B Mario Pinto
Journal:  J Biol Chem       Date:  2012-07-31       Impact factor: 5.157

6.  Sex-dependent Differences in Liver and Gut Metabolomic Profiles With Acarbose and Calorie Restriction in C57BL/6 Mice.

Authors:  Victoria K Gibbs; Rachel A Brewer; Nathan D Miyasaki; Amit Patki; Daniel L Smith
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-01-16       Impact factor: 6.053

7.  Effect of NR-Salacia on post-prandial hyperglycemia: A randomized double blind, placebo-controlled, crossover study in healthy volunteers.

Authors:  Pravina Koteshwar; Kadur Ramamurthy Raveendra; Joseph Joshua Allan; Krishnagouda Shankargouda Goudar; Kudiganti Venkateshwarlu; Amit Agarwal
Journal:  Pharmacogn Mag       Date:  2013-10       Impact factor: 1.085

8.  Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.

Authors:  Daniel L Smith; Rachael M Orlandella; David B Allison; Lyse A Norian
Journal:  Geroscience       Date:  2020-10-02       Impact factor: 7.713

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.